By Nigel Walker, Partner & Managing Director, Energy, Utilities, and Life Sciences Services, TPI
The pharmaceutical industry is seeing a lot of mergers and acquisitions as companies seek ways to reduce costs even while they can see a drop in their future revenues looming due to drugs coming off patent. But mergers will not deliver savings or revenue increases if executives do not manage the integration effectively and decisively.
Big mergers have many moving pieces. The complexity is compounded by the fact that companies in the pharmaceutical space have often been traditionally been very decentralized. When you combine decentralized organizations, you run the risk of losing the advantages of a merger. For example, it’s not unusual to see HR working towards one goal, while IT works towards another. Departments, business units and integration efforts cannot be isolated.…







